Last reviewed · How we verify
NCT04591704: COVID-19-DM2
The Effect of Diabetes Mellitus on the Prognosis of Patients With COVID-19
trial testing hospitalisation, necessity of ICU, mortality rate, lung involvement in Covid19 in 2,000 participants. Status unknown.
15 October 2020
Quick facts
| Lead sponsor | Uşak University |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 2,000 |
| Start date | 20 March 2020 |
| Primary completion | 15 October 2020 |
| Estimated completion | 1 July 2021 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- hospitalisation, necessity of ICU, mortality rate, lung involvement
Conditions studied
- Covid19 — all drugs for Covid19 →
- Diabetes Mellitus — all drugs for Diabetes Mellitus →
Sponsor
Uşak University
Who can join
Adults 18 to 80, any sex, with Covid19 or Diabetes Mellitus. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
All hospitalised patients with COVID-19 who have positive RT-PCR for SARS-COV-2 will be included in the study. The patients will be divided into two groups, as diabetics and non-diabetics. The COVID-19 patients' medical records will be evaluated and compared in terms of the duration of hospitalization, the presence of lung involvement in Computerised Tomography, the need for intensive care unit and mortality rates in patients with and without diabetes.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04591704
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Covid19
Currently open trials in the same condition.
- NCT03305341 — Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix · EARLY_PHASE1 · active not recruiting
- NCT06482138 — Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation · NA · recruiting
- NCT04924803 — Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs · NA · active not recruiting
- NCT05013632 — COVID-19 International Drug Pregnancy Registry · recruiting
- NCT04806061 — Urine Alkalinisation in COVID-19 · NA · active not recruiting
Other Uşak University trials
Trials by the same sponsor.
- NCT07356362 — High-power Laser Therapy for Notalgia Paresthetica. · NA · not yet recruiting
- NCT07328360 — The Efficacy of High-Power Laser Therapy in Meralgia Paresthetica · NA · recruiting
- NCT07276477 — Inspiratory Muscle Training After Stroke · NA · recruiting
- NCT07296380 — Manual Therapy Behavior Scale in Physiotherapists · enrolling by invitation
- NCT07296367 — Physiotherapy and Disaster · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04591704 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Uşak University
- Last refreshed: 4 May 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04591704.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing